Neuralstem, Inc. (NYSE MKT: CUR) today published a blog post entitled “An ounce of action is worth a ton of theory” on the Company’s website (http://neuralstem.com/neuralstem-ceo-blog/187-an-ounce-of-action-is-worth-a-ton-of-theory) which was republished on TheChairmansBlog.com.
Neuralstem’s President and CEO, Richard Garr, published a new blog about the company’s Phase II ALS trial. In it, he writes about three areas in which Neuralstem aims to make progress “…that will be essential in pushing the cell therapy to a Phase III trial where [the company hopes] to show efficacy in a statistically powered trial.”
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed dosing of the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, in August 2012; the trial ends six months after that last surgery. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.
TheChairmansBlog.com is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, TheChairmansBlog.com staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.
- Canada International News